drugset
drugset / Trial / NCT01826773

CardioPET as PET Imaging Agent to Assess Myocardial Perfusion and Fatty Acid Uptake in Known or Suspected CAD Subjects

NCT01826773 ↗

Phase 2 Completed 34 enrolled Fluoropharma, Inc.
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

The study is designed to evaluate how safe and how well an investigational imaging product CardioPET™ performs as compared to standard approved imaging products in assessing the function of heart muscle in coronary artery disease patients.

Timeline

Start
2013-03
Primary completion
2016-07
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Subject PARENT OF CARDIOPET Diagnostic / imaging agent 296 mbq Intravenous

Indications

coronary artery disorder